Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/568643


Lung Cancer Drug Discoveries: What The Future Holds


Description: Lung cancer affects more than 1.2 million patients a year, with around 1.1 million deaths annually and 500,000 in the US, Europe and Japan.

Non-small cell lung cancer (NSCLC) is one of the leading causes of death, resulting in the worst survival rates for all cancers and killing more patients than breast, colon and prostate cancer together, accounting for nearly 30% of all cancer deaths. According to the WHO, NSCLC affects more than 1.2 million patients a year, with around 1.1 million deaths annually and around 500,000 in the US, Europe and Japan.

The NSCLC market was estimated to be worth US$3.7 billion in 2006 with a growth rate of 14% YoY. According to PhRMA it is one of the most actively researched cancers with nearly 100 drugs in the US being evaluated in clinical trials during 2006.

As researchers begin to understand the processes involved in NSCLC formation several new targeted therapies have evolved which modulate growth factor pathways. Two small-molecular tyrosine kinase inhibitors, Iressa (AstraZeneca) and Tarceva (Roche/Genentech/OSI Pharmaceuticals), and the anti-angiogenic vascular endothelial growth factor inhibitor, Avastin (Roche/Genentech/Chugai), are gaining credence in third-line therapy and are beginning to migrate to second-line therapy.

By 2012, we anticipate at least four new chemotherapeutic agents will be launched including sanofi-aventis’ Eloxatin, Hana Biosciences’ Talvesta, Cell Therapeutics/Novartis’ Xyotax and AstraZeneca/Abraxis BioScience's Abraxane. These may have been approved to be used in combination with existing treatment protocols and in some cases may replace older products.

Key questions answered include:

-The addressable NSCLC market will increase by 17% by 2012 – what are the factors driving this?
-By 2012, products yet to be launched will account for over 50% of global NSCLC drug sales. What are they, who’s developing them and when are they expected to launch?
-What are the prospects for CancerVax, Biomira, Alfacell, Transgene and others in the hotly contested NSCLC vaccine market?
-How will the newer cytotoxics such as Eloxatin (sanofi-aventis) and satraplatin (GPC Biotech/ Pharmion/Spectrum Pharmaceuticals) fare against currently available therapies?

About the Author

Dr Cheryl Barton is a highly regarded independent consultant with over 15 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer’s disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthélabo, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton founded a consulting business (www.Pharmavision.co.uk) to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.


Contents: VOLUME 1
Executive Summary
Breast Cancer
The Facts
Patient Statistics
Patient Model
The Market
Global Cancer Market
The Breast Cancer Market
Current Treatments
Chemotherapy
Targeted Therapy
Research & Development Of BC Drugs
Competitor Ratio Analysis - Products
Competitor Ratio Analysis - Companies
Discontinuation Of Drugs
Appendix 1
Appendix 2
Appendix 3
Appendix 4
Appendix 5
Appendix 6
Glossary
Bibliography
Website References
Acronyms
Colorectal Cancer
The Facts
Global Cancer Market
The CRC Market
Current Treatments
Chemotherapy
Immunotherapy
Research & Development Of CRC Drugs
Competitor Ratio Analysis - Products
Competitor Ratio Analysis - Companies
Discontinuation Of Drugs
Appendix 1
Appendix 2
Appendix 3
Appendix 4
Appendix 5
Appendix 6
Glossary
Bibliography
Acronyms

VOLUME 2
Non-Small Cell Lung Cancer
3the Facts
Global Cancer Market
The NSCLC Market
Research & Development Of NSCLC Drugs
Competitor Ratio Analysis - Products
Discontinuation Of NSCLC Drugs
Appendix 1
Appendix 2
Appendix 3
Appendix 4
Appendix 5
Appendix 6
Bibliography
Glossary
Acronyms
Prostate Cancer
The Facts
Global Cancer Market
Competitor Ratio Analysis - Products
Discontinuation Of Drugs
Appendix 1
Appendix 2
Appendix 3
Appendix 4
Appendix 5
Appendix 6
Glossary
References
Acronyms
Renal Cell Carcinoma
The Facts
The Market
Competitor Ratio Analysis - Products
Discontinuation Of Drugs
Appendix 1
Appendix 2
Appendix 3


Products Mentioned CURRENT PRODUCTS EVALUATED AND FORECAST CHEMOTHERAPY - Taxotere (sanofi-aventis) - Taxol (BMS) - Navelbine (GSK) - Gemzar (Eli Lilly) - Alimta (Eli Lilly) TARGETED THERAPIES - Iressa (AstraZeneca) - Tarceva (Roche/Genentech) - Avastin (Roche/Genentech/Chugai) UP AND COMING PRODUCTS EVALUATED PHASE III - Recentin (AstraZeneca) - Eloxatin (sanofi-aventis) - Erbitux (BMS/Merck Serono/ImClone Systems) - PF-3,512,676 (Pfizer/Coley Pharmaceutical) - Stimuvax (Merck Serono/ Biomira) - Talabostat (Point Therapeutics) - Xyotax (Novartis/Chugai/Cell Therapeutics) - Zactima (AstraZeneca) PHASE II - Abraxane (AstraZeneca/ - Abraxis BioScience) - EP-2101 (IDM Pharma) - Matuzumab (Merck Serono/ Takeda) - Onconase (Alfacell) - Satraplatin (GPC Biotech/Pharmion/Spectrum Pharmaceuticals) - Talvesta (Hana Biosciences) - TG4010 (Transgene) - Velcade (J&J/Millennium Pharmaceuticals).


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/568643

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 05/09/2008 09:32:50
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Lung Cancer Drug Discoveries: What The Future Holds
Web Address:
http://www.researchandmarkets.com/reports/568643
Office Code:
OCHHGHMRPPZ

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €1,195.00
Hard Copy €1,195.00 + EUR€ 50.00 Shipping/Handling *

* Shipping/Handling is only charged once per order.


Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 05/09/2008 09:32:50

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World